nach oben

Current Hepatology Reports

Erschienen in:

02.05.2019 | Hepatitis C (H Vargas and S Flamm, Section Editors)

HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?

verfasst von: Javier Crespo, Susana Llerena, Carmen Cobo, Joaquin Cabezas, Antonio Cuadrado

Erschienen in: Current Hepatology Reports | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

In this review, the peculiarities of infection and treatment of HCV in the prison population are detailed. In addition, the barriers to HCV treatment and possible solutions are highlighted.

Recent Findings

Several previous experiences of HCV treatment in prisons have been successful. In this manuscript, we detail the most relevant.

Summary

We think that incarceration should be considered an opportunity to engage this population in health care. Therefore, we should encourage systematic screening of these patients and promote the access to treatment by supporting equity with the general population. Thus, inmates’ care must involve a multidisciplinary team. To solve this matter, we propose telehealth to bring together all these services and overcome the geographical barrier(s) and improve costs. Then, to go further in hepatitis C elimination, harm-reduction programs should be added to treat with direct-acting antivirals.

•• Polaris Observatory HCVC. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. Lancet Gastroenterol Hepatol. 2017;2(3):161–76. https://doi.org/10.1016/S2468-1253(16)30181-9 Main epidemiological study of hepatitis C infection worldwide.CrossRef

Cuadrado A, Perelló C, Llerena S, Gómez M, Escudero MD, Rodriguez L, et al. Estudio de la prevalencia de la Hepatitis C en la población española. Estudio PREVHEP / Cohorte ETHON. Gastroenterol Hepatol. 2107;40(Suppl E1):1.

Rodriguez-Tajes S, Dacal Y, Collazos C, Frías MC, Vidal Benede MJ, Jané M, et al. Estudio de prevalencia por los virus de la hepatitis B y C en Cataluña. Gastroenterol Hepatol. 2017;40(Suppl. E1):13.

Varan AK, Mercer DW, Stein MS, Spaulding AC. Hepatitis C seroprevalence among prison inmates since 2001: still high but declining. Public Health Rep. 2014;129(2):187–95.CrossRefPubMedPubMedCentral

Sterling RK, Cherian R, Lewis S, Genther K, Driscoll C, Martin K, et al. Treatment of HCV in the department of corrections in the era of oral medications. J Correct Health Care. 2018;24(2):127–36.CrossRefPubMed

Saiz de la Hoya P, Marco A, Garcia-Guerrero J, Rivera A. Prevalhep study g. Hepatitis C and B prevalence in Spanish prisons. Eur J Clin Microbiol Infect Dis. 2011;30(7):857–62.CrossRefPubMed

Cunningham EB, Hajarizadeh B, Bretana NA, Amin J, Betz-Stablein B, Dore GJ, et al. Ongoing incident hepatitis C virus infection among people with a history of injecting drug use in an Australian prison setting, 2005-2014: the HITS-p study. J Viral Hepat. 2017;24(9):733–41.CrossRefPubMed

Gobierno de Cataluña. Descripción estadística en los servicios penitenciarios 2018 Available from: http://www.gencat.cat/justicia/estadistiques_serveis_penitenciaris/1_pob.html. Accessed 15 Jan 2019.

Ministerio de Sanidad, Servicios Sociales e Igualdad. Plan Estratégico para el Abordaje de la Hepatitis C en el Sistema Nacional de Salud. 2015 Available from: https://www.mscbs.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan_estrategico_hepatitis_C.pdf. Accessed 15 Jan 2019.

10.

Niveau G. Prevention of infectious disease transmission in correctional settings: a review. Public Health. 2006;120(1):33–41.CrossRefPubMed

11.

Csete J, Kamarulzaman A, Kazatchkine M, Altice F, Balicki M, Buxton J, et al. Public health and international drug policy. Lancet. 2016;387(10026):1427–80.CrossRefPubMedPubMedCentral

12.

Binswanger IA, Krueger PM, Steiner JF. Prevalence of chronic medical conditions among jail and prison inmates in the USA compared with the general population. J Epidemiol Community Health. 2009;63(11):912–9.CrossRef

13.

Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388(10049):1089–102.CrossRefPubMed

14.

Baillargeon J, Black SA, Leach CT, Jenson H, Pulvino J, Bradshaw P, et al. The infectious disease profile of Texas prison inmates. Prev Med. 2004;38(5):607–12.CrossRefPubMed

15.

Piselli M, Attademo L, Garinella R, Rella A, Antinarelli S, Tamantini A, et al. Psychiatric needs of male prison inmates in Italy. Int J Law Psychiatry. 2015;41:82–8.CrossRefPubMed

16.

Piselli M, Elisei S, Murgia N, Quartesan R, Abram KM. Co-occurring psychiatric and substance use disorders among male detainees in Italy. Int J Law Psychiatry. 2009;32(2):101–7.CrossRefPubMed

17.

Esposito M. The health of Italian prison inmates today: a critical approach. J Correct Health Care. 2010;16(3):230–8.CrossRefPubMed

18.

Fazel S, Baillargeon J. The health of prisoners. Lancet. 2011;377(9769):956–65.CrossRefPubMed

19.

Zampino R, Coppola N, Sagnelli C, Di Caprio G, Sagnelli E. Hepatitis C virus infection and prisoners: epidemiology, outcome and treatment. World J Hepatol. 2015;7(21):2323–30.CrossRefPubMedPubMedCentral

20.

Ministerio del Interior; Secretaría General de Instituciones Penitenciarias. The Spanish prison system 2014 [Available from: http://www.institucionpenitenciaria.es/web/export/sites/default/datos/descargables/publicaciones/SIS._PENITENCIARIO_2014_ING_acc_2.pdf. Accessed 15 Jan 2019.

21.

Aranda-Ocaña M. European Prison Observatory. Alternatives to prison in Europe. Spain: European Prison Observartory; 2015 [updated October 2015. Available from: http://www.prisonobservatory.org/alternatives/ALTERNATIVES%20TO%20PRISON%20IN%20EUROPE.%20SPAIN.pdf. Accessed 15 Jan 2019.

22.

•• Vroling H, Oordt-Speets AM, Madeddu G, Babudieri S, Monarca R, O’Moore E, et al. A systematic review on models of care effectiveness and barriers to hepatitis C treatment in prison settings in the EU/EEA. J Viral Hepat. 2018;25(12):1406–22. https://doi.org/10.1111/jvh.12998 Complete and updated review in hepatitis C management in prison.CrossRefPubMed

23.

Redman JS, Sterling RK. Treating HCV in a captive audience: eradication efforts in the prison microenvironment. Am J Gastroenterol. 2018;113(11):1585–7.CrossRefPubMed

24.

Juan J, de la Hoya PS, Marco A, Anton JJ, Faraco I, Yllobre C, et al. Multicenter study on the discontinuation and efficacy of chronic hepatitis C treatment in the Spanish penitentiary population (EPIBAND study). Eur J Gastroenterol Hepatol. 2014;26(10):1083–9.CrossRefPubMed

25.

Marco A. Tasa y causas de discontinuación del tratamiento con Interferón Pegilado (INFpeg) más Ribavirina (RBV) en presos tratados de HCC en Cataluña durante 2002-2008. Revista Española de Sanidad Penitenciaria. 2010;S12.

26.

Marco A. Respuesta virológica rápida extendida en presos españoles con y sin infección por vih tratados de la hepatitis crónica C con Telaprevir, Peginterferon Alfa y Ribavirina. Revista Española de Sanidad Penitenciaria. 2014;S16.

27.

Marco A. 18 meses de tratamiento con Telaprevir o Boceprevir más Interferon Pegilado y Ribavirina en presos de Cataluña. Resultados preliminares de eficacia y de discontinuación de tratamiento. Revista espanola de sanidad penitenciaria. 2014;S16.

28.

Marco-Mouriño A, Espinosa M, Jordá M, Amado E, Troncoso A, Turu E, et al. Interrupción del tratamiento de la hepatitis C crónica con antivirales de acción directa por causas de origen penitenciario en las prisiones de Cataluña. Revista espanola de sanidad penitenciaria. 2016;(S18):88.

29.

Saiz de la Hoya P, Marco A, García-Guerrero J, Faraco I, Antón J, Portilla J, et al. Estudio comparativo de la eficacia en población presa con hepatitis crónica C del tratamiento directamente observado de Ribavirina vs autoadministrado, ambos con Interferón Pegilado alfa2a directamente observado (ensayo clínico Ribadot). Revista espanola de sanidad penitenciaria. 2010(S12):2.

30.

Touzón-López C, Solé C, Gallego C, Almada G, Rodríguez L, Valls I, et al. Eficacia, seguridad y discontinuación del tratamiento de la Hepatitis C Crónica con antivirales de acción directa en las prisiones de Cataluña. Revista espanola de sanidad penitenciaria. 2016;Sup. 18:87.

31.

Allen SA, Spaulding AC, Osei AM, Taylor LE, Cabral AM, Rich JD. Treatment of chronic hepatitis C in a state correctional facility. Ann Intern Med. 2003;138(3):187–90.CrossRefPubMed

32.

Boonwaat L, Haber PS, Levy MH, Lloyd AR. Establishment of a successful assessment and treatment service for Australian prison inmates with chronic hepatitis C. Med J Aust. 2010;192(9):496–500.PubMed

33.

de Juan J, Faraco I, Saiz de la Hoya P, Marco A, Yllobre C, Da Silva A, et al. Reasons for not initating HCV treatment in prison: a subanalysis of the EPIBAND study. Rev Esp Sanid Penit. 2011;13(2):44–51.PubMed

34.

Farley JD, Wong VK, Chung HV, Lim E, Walters G, Farley TA, et al. Treatment of chronic hepatitis C in Canadian prison inmates. Can J Gastroenterol. 2005;19(3):153–6.CrossRefPubMed

35.

Iacomi F, Iannicelli G, Franceschini A, Migliorisi P, Rosati S, Piselli P, et al. HCV infected prisoners: should they be still considered a difficult to treat population? BMC Infect Dis. 2013;13:374.CrossRefPubMedPubMedCentral

36.

Lloyd AR, Clegg J, Lange J, Stevenson A, Post JJ, Lloyd D, et al. Safety and effectiveness of a nurse-led outreach program for assessment and treatment of chronic hepatitis C in the custodial setting. Clin Infect Dis. 2013;56(8):1078–84.CrossRefPubMed

37.

Maru DS, Bruce RD, Basu S, Altice FL. Clinical outcomes of hepatitis C treatment in a prison setting: feasibility and effectiveness for challenging treatment populations. Clin Infect Dis. 2008;47(7):952–61.CrossRefPubMedPubMedCentral

38.

Rice JP, Burnett D, Tsotsis H, Lindstrom MJ, Cornett DD, Voermans P, et al. Comparison of hepatitis C virus treatment between incarcerated and community patients. Hepatology. 2012;56(4):1252–60.CrossRefPubMedPubMedCentral

39.

Saiz de la Hoya P, Portilla J, Marco A, Garcia-Guerrero J, Faraco I, Anton J, et al. Directly observed therapy for chronic hepatitis C: a randomized clinical trial in the prison setting. Gastroenterol Hepatol. 2014;37(8):443–51.CrossRefPubMed

40.

Simonovic Babic J, Bojovic K, Delic D, Katanic N, Mitrovic N, Malinic J. Antiviral treatment of hepatitis C in Serbian prison setting: medical treatment outcomes and patients’ adherence. Med Pregl. 2016;69(3–4):85–91.CrossRefPubMed

41.

Strock P, Mossong J, Hawotte K, Arendt V. Access to treatment of hepatitis C in prison inmates. Dig Dis Sci. 2009;54(6):1325–30.CrossRefPubMed

42.

• Kronfli N, Linthwaite B, Kouyoumdjian F, Klein MB, Lebouche B, Sebastiani G, et al. Interventions to increase testing, linkage to care and treatment of hepatitis C virus (HCV) infection among people in prisons: a systematic review. Int J Drug Policy. 2018;57:95–103. https://doi.org/10.1016/j.drugpo.2018.04.003 Updated systematic review of hepatitis C treatment and linkage to care in prison.CrossRefPubMed

43.

• Bielen R, Stumo SR, Halford R, Werling K, Reic T, Stover H, et al. Harm reduction and viral hepatitis C in European prisons: a cross-sectional survey of 25 countries. Harm Reduct J. 2018;15(1):25. https://doi.org/10.1186/s12954-018-0230-1 To improve hepatitis C prevention, treatment is not enough, harm reduction policies are of paramount importance.CrossRefPubMedPubMedCentral

44.

Yap L, Carruthers S, Thompson S, Cheng W, Jones J, Simpson P, et al. A descriptive model of patient readiness, motivators, and hepatitis C treatment uptake among Australian prisoners. PLoS One. 2014;9(2):e87564.CrossRefPubMedPubMedCentral

45.

Organization. WH. Prisons and health 2014 [Available from: http://www.euro.who.int/__data/assets/pdf_file/0005/249188/Prisons-and-Health.pdf. Accessed 15 Jan 2019.

46.

European Monitoring Centre for Drugs and Drag Addiction. Health and social responses to drug problems: a European guide: Publicantion Office of the European Union; 2017.

47.

Stone J, Martin NK, Hickman M, Hutchinson SJ, Aspinall E, Taylor A, et al. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland. Addiction. 2017;112(7):1302–14.CrossRefPubMedPubMedCentral

48.

European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL recommendations on treatment of hepatitis C 2018. J Hepatol. 2018;69(2):461–511.CrossRef

49.

Foschi A, Casana M, Radice A, Ranieri R, d’Arminio Monforte A. Hepatitis C management in prisons: an insight into daily clinical practice in three major Italian correctional houses. Hepatology. 2016;64(5):1821–2.CrossRefPubMed

50.

Beck AJ ML. Hepatitis testing and treatment in state prisons. US Department of Justice, Office of Justice Programs 2015 [updated August 25, 2015. Available from: https://http://www.ncjrs.gov/App/abstractdb/AbstractDBDetails.aspx?id=199173. Accessed 15 Jan 2019.

51.

•• Cuadrado A, Llerena S, Cobo C, Pallas JR, Mateo M, Cabezas J, et al. Microenvironment eradication of hepatitis C: a novel treatment paradigm. Am J Gastroenterol 2018;113(11):1639–1648. https://doi.org/10.1038/s41395-018-0157-x. Spanish model to attend inmates in managing hepatitis C infection with a test-and-treat strategy supported by a telemedicine tool and multidisciplinary team..

52.

Fernández-González F, Matilla-Peña A, Gijón-Vidaurreta P, Rincón-Rodríguez D, Reigadas-Ramirez E, Clemente-Ricote G. Tratamiento con Sofosbuvir Ledipasvir en población penitenciaria española con Hepatitis crónica C. Revista Epañola de Sanidad Penitenciaria. 2016;18(Suplemento XI Congreso Nacional y XIX Jornadas de la Sociedad Española de Sanidad Penitenciaria):99.

53.

Jiménez-Galán G, Alía C, Fernández C, Velasco M, Pérez E, Montero L. Efectividad y seguridad del tratamiento con antivirales de acción directa (AAD) y su impacto en la rigidez hepática en pacientes con hepatitis crónica VHC. Experiencia en un Centro Penitenciario. Revista Epañola de Sanidad Penitenciaria. 2016;18(Suplemento XI Congreso Nacional y XIX Jornadas de la Sociedad Española de Sanidad Penitenciaria):92.

54.

Mínguez-Gallego C, Jorge-Vidal V, Serrano-Balaguer M, Vera-Remartinez E, Herrero-Matías A, García-Guerrero J. Eficacia de las terapias libres de interferón frente al VHC en el medio penitenciario. Revista Epañola de Sanidad Penitenciaria. 2016;Sup. 18(Suplemento XI Congreso Nacional y XIX Jornadas de la Sociedad Española de Sanidad Penitenciaria):96.

55.

• Marco A, Roget M, Cervantes M, Forne M, Planella R, Miquel M, et al. Comparison of effectiveness and discontinuation of interferon-free therapy for hepatitis C in prison inmates and noninmates. J Viral Hepat. 2018;25(11):1280–6. https://doi.org/10.1111/jvh.12940 Treatment hepatitis C in prison is similar to the general population in terms of efficacy.CrossRefPubMed

56.

Chhatwal JLK, He T, Roberts M, Ayer T, Samur S, et al. Hepatitis C treatment in United States prisons prevents transmission and is cost- saving for the society: AASLD; 2016.

57.

Ndeffo-Mbah ML, Vigliotti VS, Skrip LA, Dolan K, Galvani AP. Dynamic models of infectious disease transmission in prisons and the general population. Epidemiol Rev. 2018;40(1):40–57.CrossRefPubMedPubMedCentral

58.

He T, Li K, Roberts MS, Spaulding AC, Ayer T, Grefenstette JJ, et al. Prevention of hepatitis C by screening and treatment in U.S. prisons. Ann Intern Med. 2016;164(2):84–92.CrossRefPubMed

59.

Tan JA, Joseph TA, Saab S. Treating hepatitis C in the prison population is cost-saving. Hepatology. 2008;48(5):1387–95.CrossRefPubMed

60.

Liu S, Watcha D, Holodniy M, Goldhaber-Fiebert JD. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis. Ann Intern Med. 2014;161(8):546–53.CrossRefPubMedPubMedCentral

61.

Chhatwal J, Samur S, Li K, He T, Llerena S, Cobo C, et al. Improved health outcomes from hepatitis C treatment scale-up in Spain’s prisons: a cost-effectiveness study. J Hepatol. 2018;68:S151.CrossRef

62.

Munang M, Smit E, Barnett T, Atherton C, Tahir M, Atabani SF. Outcomes and costs of single-step hepatitis C testing in primary care, Birmingham, United Kingdom. Public health. 2018;166:40–4.CrossRef

63.

Coats JT, Dillon JF. The effect of introducing point-of-care or dried blood spot analysis on the uptake of hepatitis C virus testing in high-risk populations: a systematic review of the literature. Int J Drug Policy. 2015;26(11):1050–5.CrossRefPubMed

64.

EMCDDA. European Monitoring Centre for Drugs and Drug Addiction Prisons and drugs in Europe: the problem and responses Lisbon. EMCDDA. 2012.

65.

Sander G, Murphy F. The furthest left behind: the urgent need to scale up harm reduction in prisons. Int J Prison Health. 2017;13(3–4):185–91.CrossRefPubMed

66.

Arora S, Kalishman S, Thornton K, Dion D, Murata G, Deming P, et al. Expanding access to hepatitis C virus treatment--extension for community healthcare outcomes (ECHO) project: disruptive innovation in specialty care. Hepatology. 2010;52(3):1124–33.CrossRefPubMedPubMedCentral

67.

Thornton PSM, Arora S. Treatment of chronic hepatitis C virus (HCV) with direct acting antivirals in the New Mexico state prison system using the ECHO model. J Hepatol. 2017;66(1):S1–S876.CrossRef

68.

Gonzalez JC, Ayesa R, Setién E, Iruzubieta P, Estébanez Á, Crespo-Facorro B, et al. Direct acting antiviral treatment improves hepatitis C-related neurocognitive impaiment. J Hepatol. 2018;68:S271.CrossRef

69.

Llerena S, Mateo M, Cobo C, Blasco A, Cabezas J, Lázaro P, et al. Efficiency of a telemedicine program in the management of hepatitis C in inmates. Hepatology. 2018;68(S1):1–183.

Titel: HCV Management in the Incarcerated Population: How Do We Deliver on This Important Front?
verfasst von: Javier Crespo
Susana Llerena
Carmen Cobo
Joaquin Cabezas
Antonio Cuadrado
Publikationsdatum: 02.05.2019
Verlag: Springer US
Erschienen in: Current Hepatology Reports / Ausgabe 2/2019
Elektronische ISSN: 2195-9595
DOI: https://doi.org/10.1007/s11901-019-00472-2

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Echinokokkose medikamentös behandeln oder operieren?

06.05.2024 DCK 2024 Kongressbericht

Die Therapie von Echinokokkosen sollte immer in spezialisierten Zentren erfolgen. Eine symptomlose Echinokokkose kann – egal ob von Hunde- oder Fuchsbandwurm ausgelöst – konservativ erfolgen. Wenn eine Op. nötig ist, kann es sinnvoll sein, vorher Zysten zu leeren und zu desinfizieren.

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Proximale Humerusfraktur: Auch 100-Jährige operieren?

01.05.2024 DCK 2024 Kongressbericht

Mit dem demographischen Wandel versorgt auch die Chirurgie immer mehr betagte Menschen. Von Entwicklungen wie Fast-Track können auch ältere Menschen profitieren und bei proximaler Humerusfraktur können selbst manche 100-Jährige noch sicher operiert werden.

Die „Zehn Gebote“ des Endokarditis-Managements

30.04.2024 Endokarditis Leitlinie kompakt

Worauf kommt es beim Management von Personen mit infektiöser Endokarditis an? Eine Kardiologin und ein Kardiologe fassen die zehn wichtigsten Punkte der neuen ESC-Leitlinie zusammen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Purpose of Review

Recent Findings

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

HCV Exposure in the Health Care Arena. Is there a Role for Post-exposure Prophylaxis?

Patient Selection in Transjugular Intrahepatic Portosystemic Shunt (TIPS) for Refractory Ascites and Associated Conditions

Novel Targets and Drug Development in Portal Hypertension

Hepatitis C-Positive Organs for Liver and Kidney Transplantation—Emerging Data and Current Management Strategies

Acute HCV Treatment: What Should We Do in the DAA Era?

Non-invasive Fibrosis Assessment of Patients with Hepatitis C: Application of Society Guidelines to Clinical Practice